Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.57 |
| ▸ | GRM5 | P41594 | 11/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12537886 | 0.93 | GRM1 (0.55) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL17837639 | 0.91 | GRM1 (0.57) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL29150145 | 0.91 | GRM1 (0.57) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL30308912 | 0.91 | GRM1 (0.64) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL9111083 | 0.91 | GRM1 (0.52) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL23362181 | 0.86 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL4299295 | 0.86 | HTR1A (0.43) | GRM1GRM5PDK4 | |
| SCHEMBL16544582 | 0.86 | GRM5 (0.59) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL29664333 | 0.86 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL5337540 | 0.85 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265600-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | GRM1 82/4885GRM5 60/4885PDK4 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.